| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8652516 | The Annals of Thoracic Surgery | 2018 | 22 Pages |
Abstract
Our results suggest that the value of PD-L1 mRNA in prognosticating outcome in lung cancer is limited. Further studies are needed to identify novel prognostic biomarkers other than PD-L1 that are associated with improved patient survival. Identification of further prognostically important biomarkers may prove useful in identifying patients suitable for immunotherapy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Boris MD, David B. MD, Kyle G. MD, Don L. MD, John V. MD, PhD, Ara A. MD, Stephen G. MD, Jason PhD, MBA,